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Sarcomas are malignant neoplasms of mesenchymal origin which,
like other malignancies, are characterized by unbalanced cellular
proliferation and genomic instability. One hypothesis, which may
help explain their neoplastic phenotype, is that they arise as a
consequence of a cell cycle checkpoint defect (Hartwell, 1992;
Paulovich et al, 1997). Support for this hypothesis comes from the
observation that many of the molecules that regulate cell cycle
checkpoints in eukaryotic cells are direct targets for deregulation
in human cancers. p53 protein for example is a critical component
of a pathway that regulates the cell cycle at the G1/S phase in
response to DNA damage (Waldman et al, 1995; Levine, 1997). In
addition to p53 protein, other molecules in this pathway have been
shown to be altered in human cancer cells (Hollstein et al, 1991;
Hartwell, 1992; Kastan et al, 1992; Waldman et al, 1995; Levine,
1997). A number of groups, including our own (Mousses et al,
1996), have reported that the p53 gene is frequently targeted for
deregulation in bone and soft tissue sarcomas. The retinoblastoma
(RB) gene product, which functions downstream of p53 is also
commonly altered in sarcomas (Reissmann et al, 1989; Wunder 
et al, 1991). Interestingly, both p53 and RB germ-line mutations
predispose individuals to the development of sarcomas (Malkin 
et al, 1990; Bookstein and Lee, 1991). Other downstream genes,
including MDM-2, which regulates p53 function (Finaly, 1993)
and p53 protein expression, as well as CDK4, have been shown to
be over-expressed and amplified in certain sarcomas (Khatib et al,
1993; Cordon-Cardo et al, 1994; Wunder et al, 1999). 
A recently identified member of the p53-dependent DNA
damage response pathway is the CDK inhibitor p21CIP1/WAF1
(El-Deiry et al, 1993; Harper et al, 1993; Xiong et al, 1993; Noda
et al, 1994). In the presence of DNA damage, p53 leads to the tran-
scriptional activation of p21CIP1/WAF1, via a responsive element in its
promoter, and increased p21CIP1/WAF1 expression then mediates a
cell cycle arrest (El-Deiry et al, 1993, 1994). Increased levels of
p21CIP1/WAF1 cause inhibition of CDK/cyclin complexes and cell
cycle arrest at the G1/S phase (Harper et al, 1993). Since its initial
discovery, p21CIP1/WAF1 has been observed to be regulated by both
p53-dependent and independent mechanisms (El-Deiry et al,
1994; Macleod et al, 1995). Elevated p21CIP1/WAF1 levels affect a
wide range of cellular processes besides cell cycle checkpoints,
including senescence and differentiation (El-Deiry et al, 1994;
Macleod et al, 1995). There is mounting evidence that p21CIP1/WAF1
is also targeted for deregulation in human cancer cells (El-Deiry 
et al, 1995; Ozcelik et al, 1995; Matsushita et al, 1996; Hui et al,
1997). Despite the fact that somatic mutations are not a common
mechanism of inactivating p21CIP1/WAF1 function (Shiohara et al,
1994; Koopmann et al, 1995; Mousses et al, 1995; Sun et al, 1995;
Watanabe et al, 1995; Wan et al, 1996), cancer cells often have
very low levels of p21CIP1/WAF1 in comparison to their normal coun-
terparts (El-Deiry et al, 1995; Ozcelik et al, 1995; Matsushita
et al, 1996; Hui et al, 1997). Furthermore, p21CIP1/WAF1, which is
normally found in a complex with a cyclin, cdk and PCNA, is
often missing from this quaternary complex in cancer cell lines
(Xiong et al, 1993). The in vivo mechanisms leading to p21 dereg-
ulation and the consequences on the phenotype of the cancer cell
are largely unknown and the topic of intense investigation. 
Mutation of p53 gene has been shown to inactivate its ability to
transcriptionally activate downstream genes (Chen et al, 1993;
Levine, 1997), including p21CIP1/WAF1, leading to loss of cell cycle
control (Li et al, 1994). In support of this, several studies have
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state levels of p21CIP1/WAF1 expression than tumours without such
mutations (Ozcelik et al, 1995; Matsushida et al, 1996; Hui et al,
1997). We have investigated this association in human breast
cancer and observed that tumours with p53 mutations had a signif-
icantly lower distribution of p21CIP1/WAF1 mRNA levels compared to
tumours without detectable p53 mutation (Ozcelik et al, 1995). 
In a study of bone and soft tissue sarcomas, we had previously
found that 15 to 30% of sarcomas have p53 mutations (Mousses 
et al, 1996). In this report we examined whether p21CIP1/WAF1 gene
expression was deregulated in primary human sarcoma specimens.
To this end, we determined the level of p21CIP1/WAF1 mRNA in a
group of 71 bone and soft tissue sarcoma specimens and compared
p21CIP1/WAF1 mRNA expression with p53 mutational status. 
MATERIAL AND METHODS 
Clinical data and tumour samples 
Specimens were obtained from 71 patients with biopsy proven
bone or soft tissue sarcoma. For each case, a surgically obtained
tumour sample was chosen by a pathologist with the aid of frozen
histologic analysis to determine that only viable tumour with-
out contamination by surrounding normal tissue was chosen.
Specimens were immediately snap frozen and stored at –70˚C.
RNA was extracted by the guanidinium thiocyanate-cesium
chloride gradient method (Chomczynski and Sacchi, 1987). 
There were 51 bone sarcomas (mostly osteosarcoma and chon-
drosarcoma) and 20 soft tissue sarcomas (mostly liposarcoma and
malignant fibrous histiocytoma). Most patients presented with a
localized tumour (n = 66), while 5 had metastases present at the
time of diagnosis. Treatment information was available for most
patients. For 31 patients, the biopsy was followed by surgical
excision of the primary tumour. However, 30 patients received
neoadjuvant treatment prior to surgical resection. In general,
preoperative treatment for patients with high-grade bone sarcomas
consisted of adriamycin-based chemotherapy, while soft tissue
sarcomas received 50 Gray local radiation. Tumour excision
was usually performed 3–4 weeks following the completion of
preoperative therapy. 
Analysis of mRNA expression by quantitative RT-PCR 
cDNA synthesis and quantitative RT-PCR assays of p21CIP1/WAF1
mRNA were performed essentially as described in Ozcelik et al
(1995). CDNA was reverse-transcribed from 100 ng of total
cellular RNA with random hexadeoxynucleotide primers and
Moloney murine leukaemia reverse transcriptase (MMLV-RT). A
fragment of p21CIP1/WAF1 (5¢-AAGACCATGTGGACCTGTCA-3¢
and 5¢-GGCTTCCTCTTGGAGAAGAT-3¢ length of PCR
product: 170 bp), and an internal control gene phosphoglycerate
kinase (PGK) (5¢-CAGTTTGGAGCTCCTGGAAG-3¢ and 5¢-
TGCAAATCCAGGGTGCAG TG-3¢ length of PCR product: 247
bp), were amplified in the same PCR reaction using Taq DNA
polymerase. PGK was chosen as an internal control to account for
variations in the quality of mRNA originally used and for varia-
tions in the PCR kinetics. Reactions were conducted over a range
of cycles (22–28 cycles) in order to allow quantitative evaluation
within the logarithmic phase of the PCR reaction.The PCR prod-
ucts were separated by PAGE, and quantified by laser densitom-
etry (Molecular Dynamics). The expression of p21CIPI/WAFI was
calculated as the ratio of the intensity of the PCR fragments for
p21CIPI/WAFI to PGK (averaged over 2 cycle points within the loga-
rithmic phase) relative to the breast cancer cell line, MCF-7. 
Statistical analysis 
Comparisons in p21 levels among treatment groups and among
p53 groups were conducted by exact P value calculations using
Fisher’s exact test for 2 by 2 tables and its generalization for 2 by
3 tables. Exact 95% confidence intervals (CI) were constructed to
assess the precision of the observed differences in proportions. 
RESULTS 
Expression of p21CIPI/WAFI mRNA in sarcomas 
The steady state levels of p21CIPI/WAFI mRNA were quantified by
RT-PCR in 71 bone and soft-tissue tumours. Relative to an internal
control gene, PGK, the levels of p21CIPI/WAFI expression were found
to vary among tumours over a 10-fold range (Figure 1). An
osteoblast cell line used as a normal control exhibited a relative
level of expression of 0.72 (data not shown), and served to distin-
guish between tumours with low and high p21 expression. A
number of sarcomas had very low levels of p21CIPI/WAFI expression
when compared to the normal osteoblast cell line. 
p53 mutations and p21 mRNA expression 
We had previously detected p53 mutations in 29 of the 71 sarcoma
specimens (Mousses et al, 1996; Gokgoz et al, submitted). When the
p53 status was compared with the p21CIPI/WAFI mRNA expression
level (Figure 1) we found that in tumours with and without
detectable p53 mutations, the levels of p21CIPI/WAFI mRNA were
distributed throughout the entire range of expression. There was no
significant difference in p21 levels between tumours with and
without p53 mutations (P = 0.76). The majority of tumours with
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Figure 1 Distribution of mRNA p21CIP1/WAF1 expression in sarcomas of
different p53 status. A fragment of p21CIP1/WAF1 and an internal control gene
phosphoglycerate kinase (PGK) were amplified simultaneously. PGK was
chosen as an internal control to account for variations in the quality of mRNA
originally used and for variations in the PCR kinetics. Reactions were
conducted over a range of cycles (22–28 cycles) in order to allow quantitative
evaluation within the logarithmic phase of the PCR reaction. The PCR
products were separated by PAGE, and quantified by laser densitometry
(Molecular Dynamics). The expression of p21CIP1/WAF1 was calculated as the
ratio of the intensity of the PCR fragments for p21CIP1/WAF1 to PGK relative to
the tumour cell line MCF-7. The distribution of p21C1P1/WAF1 mRNA levels is
shown for sarcomas with and without detectable p53 mutations mutant p53 (19 of 29, 66%) and wild-type p53 (29 of 42, 69%)
expressed low levels of p21CIPI/WAFI mRNA relative to the normal
osteoblast cell line. However, there were 10 tumours with p53 muta-
tions that exhibited normal or higher levels of p21CIPI/WAFI mRNA. 
Association of missense mutations with low levels of
p21CIPI/WAFI mRNA 
To explore whether the specific type of p53 mutation was
associated with the level of expression of p21CIPI/WAFI mRNA, we
compared the type of p53 mutation (missense vs. other) in tumours
with low levels versus tumours with high p21CIPI/WAFI levels. Of the
19 tumours with p53 mutations that expressed low levels of
p21CIPI/WAFI, 17 had missense mutations (Table 1). In contrast, only
2 of the 10 tumours with p53 mutations and high levels of
p21CIPI/WAFI mRNA exhibited missense alterations (in codons 244
and 245). The majority of tumours with high p21CIPI/WAFI levels (8
of 10) exhibited p53 mutations leading to stop codons that would
potentially produce truncated forms of the p53 protein. The
Fisher’s exact test indicated a statistically significant association
of missense mutations with low levels of p21CIPI/WAFI mRNA
(P = 0.0004). 
The effect of pre-operative treatment on p21 expression 
We did not detect an association between p21CIPI/WAFI mRNA level
and tumour grade, presentation with a primary versus metastatic
lesion or locally recurrent tumour, or bone versus soft tissue
sarcoma (Fisher’s exact test P > 0.05). We did, however, observe a
statistically significant association between p21CIPI/WAFI mRNA
level and treatment. Treatment information was available for 61 of
the patients in this study. 30 patients received either preoperative
chemotherapy or radiotherapy prior to tumour resection; whereas
the other 31 patients did not. In the untreated group, 22.6% (7 of
31) of tumours expressed high levels of p21CIPI/WAFI mRNA
whereas 50% (15 of 30) of the treated group had elevated
p21CIPI/WAFI mRNA (exact P = 0.034; difference in proportions = 27
(percentage units) with exact 95% CI of (1, 52)). A similar treat-
ment difference was observed when the analysis was limited to the
group of tumours with wild-type p53, although it did not attain
conventional statistical significance (exact P = 0.075, difference =
32 with exact 95% CI of (–2, 65)) (Table 2). 
In the untreated group, significant differences in p21CIPI/WAFI
mRNA expression were observed among the 3 p53 groups (exact
P = 0.003). None of 9 tumours (0%) with missense mutations and
4 of 19 tumours (21%) without p53 mutations had high p21CIPI/WAFI
levels; whereas all 3 of the tumours with nonsense mutations
(100%) expressed high levels of p21CIPI/WAFI mRNA. A similar
pattern of differences was observed in the treated group (25, 53,
71% with high p21CIPI/WAFI in missense, wild-type, and nonsense
groups, respectively), but was not statistically significant (exact 
P = 0.25). Although the p21CIPI/WAFI differences between missense
and nonsense groups were greater in the untreated group than in
the treated group (exact P values of 0.005 and 0.13, respectively,
with P = 0.001 in the combined group), the 95% CIs for the 2
groups were wide and had substantial overlap. 
p21CIP1/WAF1 expression in human sarcoma 1637
British Journal of Cancer (2001) 84(12), 1635–1639 © 2001 Cancer Research Campaign
Table 1 p53 mutations and p21CIP1/WAF1 expression 
Type of sarcoma p53 Codon Mutation  p21CIP1/WAF1 mRNA 
Osteosarcoma 337 Arg > Cys 0.19 
Osteosarcoma intron 8 splicing 0.23 
Rhabdomyosarcoma 132 Lys > Glu 0.26 
Osteosarcoma Immunohistochemistry positive  anot done 0.32 
Osteosarcoma 248 Arg > Gln 0.33 
Osteosarcoma 248 Arg > Gln 0.35 
Osteosarcoma 248 Arg > Gln 0.35 
Osteosarcoma Immunohistochemistry positive  anot done 0.39 
Osteosarcoma 273 Arg > His 0.42 
Osteosarcoma 47 Pro > Leu 0.42 
Osteosarcoma 281 Asp > His 0.45 
Liposarcoma 276 Ala > Pro 0.46 
Osteosarcoma 256 Thr > Ser 0.49 
Osteosarcoma 237 Met > Ile 0.51 
Osteosarcoma 202–206 in frame deletion  0.51 
Osteosarcoma 220 Tyr > Cys 0.59 
Osteosarcoma 250 Pro > Leu 0.59 
Osteosarcoma 273 Arg > His 0.63 
Osteosarcoma 242 Cys > Tyr 0.66 
Liposarcoma 244 Gly > Ser 0.79 
Osteosarcoma 342 Arg > Stop 0.81 
Osteosarcoma 107/108 in frame insertion 0.84 
Osteosarcoma 204 Glu > Stop 1.00 
Osteosarcoma intron 5 splicing 1.07 
Osteosarcoma 221 Glu > Stop 1.09 
Liposarcoma 213 Arg > Stop 1.10 
Osteosarcoma 43 Leu > Stop 1.11 
Osteosarcoma 43 Leu > Stop 1.12 
Osteosarcoma 245 Gly > Ser 1.45 
aFor two samples, p53 mutations were not determined by DNA analysis but these samples exhibited strong
immunohistochemical positive staining (Mousses et al, 1996). DISCUSSION 
Down-regulation of p21CIPI/WAFI gene expression has been shown to
occur in a wide variety of human cancer cell lines. Often this
down-regulation is a result of a p53 mutation, which leads to a loss
of transcriptional activation of the p21CIPI/WAFI gene. Consequently
many tumours with p53 mutations have very low levels of
p21CIPI/WAFI. In vivo validation of genetic interactions that have
been established in vitro, however, requires the use of tumour
tissue. In this study, we investigated 2 genetic events, p53 muta-
tional status and expression of p21CIPI/WAFI mRNA, to determine
whether they are associated in primary human sarcomas. 
The steady state levels of p21CIPI/WAFI mRNA were quantified by
RT-PCR in 71 bone and soft tissue sarcomas. The expression of
p21CIPI/WAFI mRNA was found to vary among tumours over a 10-
fold range and it was observed that some, but not all, of the
sarcomas had relatively low levels when compared to the normal
osteoblast cell line. 
We found, as expected, that most tumours with p53 mutations
expressed low levels of p21CIPI/WAFI mRNA. However, we identi-
fied a group of tumours with p53 gene mutations that exhibited
normal or higher levels of p21CIPI/WAFI mRNA. The p53 mutations
in the latter group were not the common missense mutations in
exons 4–9, but were predominantly nonsense mutations predicted
to result in truncation of the p53 protein. The results of this study
suggest that different types of p53 mutations can have different
effects on the expression of downstream genes such as p21CIPI/WAFI
in human sarcomas. 
Our observation of sarcomas with p53 gene mutations that
expressed normal or high levels of p21CIPI/WAFI mRNA are in
contrast to those we previously reported in breast cancer. We had
found that with very few exceptions, breast cancers with p53
mutations had lower levels of p21CIPI/WAFI mRNA than breast
cancers with wild-type p53 (Ozcelik et al, 1995). It is possible that
in addition to p53 mutations, there may be other transcription
factors, which influence the expression of p21CIPI/WAFI, and are
tissue specific for sarcomas. This would explain why many of the
tumours with apparently low levels of p21CIPI/WAFI mRNA do not
have detectable p53 mutations. Furthermore, it may be that in
breast cancer, most of the defects on p53 function are accom-
plished directly by p53 gene mutation, whereas in sarcomas there
may be more indirect p53 function defects. For example MDM2,
which binds to and inactivates p53 and regulates the expression of
p53 protein, has been shown to be amplified in some sarcomas
(Khatib et al, 1993; Cordon-Cardo et al, 1994; Wunder et al,
1999). 
Another possibility is that different types of p53 mutations have
various effects on the ability of p53 to transcriptionally induce the
p21CIPI/WAFI promoter. For example, it has been shown in vitro that
not all p53 mutations lead to the same degree of loss of expression,
and that some mutations may produce a gain of function (Chen 
et al, 1993; Ditmer et al, 1993). 
A study by Taubert et al reported that missense p53 mutations
were associated with a worse prognosis for patients with sarcomas
when compared to non-sense mutations (Taubert et al, 1996). It
also has been observed that p53 mutants without a functional
tetramerization domain are not oncogenic (Chene and Bechter,
1999). Our data are compatible with these findings since we found
that tumours with missense mutations generally expressed lower
p21CIPI/WAFI mRNA levels than those tumours with truncation-type
mutations. Higher levels of p21CIPI/WAFI mRNA are more represen-
tative of the normal cellular expression pattern. 
There was no association between p21CIPI/WAFI mRNA level and
tumour grade, stage or type of sarcoma, however, there was a
significant association of high p21CIPI/WAFI levels with tumours
which had received preoperative treatment with either chemo-
therapy or radiation. Although the differences in p21CIPI/WAFI
expression according to p53 status in the treated group were not
significant at the 5% level, it should be recognized that only very
large differences could be detected as significant in a sample of
this size. Similarly, although the differences between missense 
and nonsense mutation were smaller in the treated group than in
the untreated group, tests for homogeneity had low power to de-
termine whether treatment modified the association between
p21CIPI/WAFI mRNA level and p53. 
In this study, we found that in primary human sarcomas,
missense p53 mutations were associated with lower levels of
p21CIPI/WAFI expression; whereas p53 truncation mutations were
associated with higher expression. These observations warrant
further investigation into the effects of various types of p53 muta-
tions on the transcriptional activation of the p21CIPI/WAFI promoter
and on the expression of other downstream genes. 
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